Principal Financial Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Principal Financial Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-25,372	Closed	-$1.16M	–	2275
2017 Q4	$1.16M	Buy	25,372 +17,370	+217%	+$866K	﹤0.01%	1820
2017 Q3	$359K	Sell	8,002 -653	-8%	-$22.3K	﹤0.01%	1993
2017 Q2	$259K	Sell	8,655 -2,046	-19%	-$50.5K	﹤0.01%	2084
2017 Q1	$237K	Sell	10,701 -446	-4%	-$9.57K	﹤0.01%	2062
2016 Q4	$210K	Sell	11,147 -1,669	-13%	-$40.8K	﹤0.01%	2088
2016 Q3	$385K	Sell	12,816 -31	-0.2%	-$964	﹤0.01%	1903
2016 Q2	$494K	Buy	+12,847	New	+$533K	﹤0.01%	1857

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Principal Financial Group's JUNO Position: Q1 2018 in Review

Principal Financial Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 25,372 shares — an estimated $1.16M sold.

Principal Financial Group first reported a position in JUNO in Q2 2016 and held it in 7 quarters. The position peaked at $1.16M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Principal Financial Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Principal Financial Group sold 25,372 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $1.16M.
Principal Financial Group first reported a position in Juno Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
Principal Financial Group's Juno Therapeutics, Inc. position peaked at $1.16M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Principal Financial Group's 13F filing for Q1 2018, filed 14 May 2018.